TP53基因突变在前列腺癌患者中的临床特征及预后价值  

Clinical features and prognostic value of TP53 gene mutation in patients with prostate cancer

作　　者：祁峰 李潇[1] 徐维章 蔡宏宙[1] 须霆[1] 喻彬[1] 邹青[1] 徐子程[1] QI Feng;LI Xiao;XU Weizhang;CAI Hongzhou;XU Ting;YU Bin;ZOU Qing;XU Zicheng(Department of Urology,Jiangsu Cancer Hospital,Cancer Hospital Affiliated to Nanjing Medical University,Nanjing,210009,China)

机构地区：[1]江苏省肿瘤医院,南京医科大学附属肿瘤医院泌尿外科,南京210009

出　　处：《临床泌尿外科杂志》2022年第12期906-910,共5页Journal of Clinical Urology

摘　　要：目的探索TP53基因在前列腺癌中的突变图谱,以及TP53突变与患者临床病理特征及预后之间的关系。方法回顾性收集2011年8月—2022年2月在南京医科大学附属肿瘤医院泌尿外科诊治的97例前列腺癌患者的基本资料、二代测序(NGS)结果及长期随访资料。对比分析TP53突变型和野生型患者临床病理特征和生存结果。通过单因素和多因素Cox回归模型分析TP53突变对总体生存和至去势抵抗性前列腺癌(CRPC)时间的影响。结果本研究中,TP53突变率为21.65%(21/97);最易发生突变的外显子是第5外显子(26.67%,8/30),最常见的突变类型是错义突变(46.67%,14/30);且组织检测突变的敏感性显著高于外周血。与TP53野生型相比,TP53突变型患者有更年轻的初诊年龄和更高的临床T分期、N分期和M分期。生存分析显示,TP53突变型患者的总体生存和至CRPC时间更短。TP53突变是影响至CRPC时间的独立危险因素。结论在前列腺癌中,TP53突变与较早的初诊年龄、不良病理特征和较差预后显著相关。此外,TP53突变是影响至CRPC时间的独立危险因素。未来仍需要前瞻性、多中心大样本研究来验证本研究的结果。Objective To explore the mutation map of TP53 gene in prostate cancer,and the relationship between TP53 mutation and clinicopathological characteristics as well as prognosis of prostate cancer patients.Methods The basic characteristics,next-generation sequencing(NGS)results and long-term follow-up of 97 prostate cancer patients who were diagnosed and treated in the department of urology,Affiliated Cancer Hospital of Nanjing Medical University from August 2011 to February 2022 were retrospectively collected.The clinicopathological features and survival outcomes of TP53 mutant and wild-type patients were compared.The effects of TP53 mutation on overall survival and time to castration-resistant prostate cancer(CRPC)were analyzed by univariate and multivariate Cox regression analyses.Results In this study,the mutation rate of TP53 was 21.65%(21/97),and exon 5 was the most susceptible to mutation(26.67%,8/30).The most common mutation type was missense mutation(46.67%,14/30),and the sensitivity of tissue to detect mutations was significantly higher than that of peripheral blood.Compared with TP53 wild-type,TP53 mutant patients had younger age at diagnosis and higher clinical T,N and M stages.Survival analyses showed that TP53 mutant patients had shorter overall survival and time to CRPC.TP53 mutation was an independent risk factor affecting time to CRPC.Conclusion In prostate cancer,TP53 mutation was significantly associated with early age at diagnosis,poor pathological features,and worse prognosis.In addition,TP53 mutation was an independent risk factor affecting the time to CRPC.Prospective,multi-center and large sample studies are needed to verify the results of this study in the future.

关 键 词：前列腺癌 TP53基因 预后 基因检测 突变 

分 类 号：R737.25[医药卫生—肿瘤]